
Housing market watch: Would taking Freddie Mac and Fannie Mae public drive up mortgage rates in 2026?
Earlier this month, President Donald Trump signed his party's reconciliation/tax overhaul bill.
With reconciliation/taxes now in the rearview mirror, Freddie Mac and Fannie Mae conservatorship could move up the docket. After all, back in May, Treasury Secretary Scott Bessent said that privatizing Fannie Mae and Freddie Mac would be on the agenda after taxes and trade deals.
'It [privatization of Fannie and Freddie] is a goal for this administration,' Treasury Secretary Scott Bessent said in May. 'Again, we're doing peace deals, tax deals, and trade deals. As we land some of those deals then we will focus on that [privatization of Fannie and Freddie]. But what I can tell you is that we are doing a great deal of studying at Treasury because the one requirement for this privatization is that they are privatized in such a way that mortgage spreads do not widen.'
One reason housing stakeholders should pay attention to the fate of Freddie Mac and Fannie Mae is the long standing concern that ending conservatorship could put upward pressure on mortgage rates. See, once released, Fannie Mae and Freddie Mac could need to hold more capital to absorb losses. To build and maintain that capital, they may need to increase guarantee fees charged to lenders. In addition, upon release, unless there's an 'explicit guarantee' or backstop from Congress, investors may demand higher returns to account for increased risk.
Those concerns are real enough that this spring, both Treasury Secretary Scott Bessent and Federal Housing Finance Agency (FHFA) director Bill Pulte said that Freddie Mac and Fannie Mae conservatorship changes wouldn't be made if doing so put upward pressure on mortgage rates/mortgage spreads.
'The priority for a Fannie and Freddie release, the most important metric that I'm looking at is any study or hint that mortgage rates would go up. Anything that is done around a safe and sound release [of Fannie Mae and Freddie Mac] is going to hinge on the effect of long-term mortgage rates,' Treasury Secretary Scott Bessent said in February.
While Bessent has suggested they're looking into 'privatization,' Pulte has indicated it's not really Fannie Mae and Freddie Mac 'privatization,' but rather taking them 'public.' To be honest, I'm not entirely sure what he's getting at. Maybe keeping them in conservatorship but selling off more shares? I'm not sure.
'At Fannie Mae we have $4.3 trillion on our balance sheet. At Freddie Mac, we have over $3 trillion,' Pulte said in May. 'I would point you to his [Trump's May] tweet. He explicitly says he wants to take them [Fannie Mae and Freddie Mac] public—he did not say he wants to privatize them or many of the other things that are out there. I think these businesses have a ton of value. These businesses one day could be worth trillions of dollars. We'll see what the president ultimately decides.'
While the U.S. Treasury owns the majority of Fannie Mae and Freddie Mac profits through senior preferred stock agreements, the common and preferred shares that existed before conservatorship were never fully wiped out.
Once Wall Street realized Trump had won the 2024 election, the stocks of Fannie Mae and Freddie Mac spiked as the market priced in higher odds that the second Trump administration would attempt to end the current status quo.
Looking at their share prices today, it's clear that either Wall Street or retail investors (or both) think something new is still on the horizon for Freddie Mac and Fannie Mae.
As noted above, Pulte made comments in May that seemed to suggest that what they're considering could just be selling off/releasing some of the Freddie Mac and Fannie Mae stocks currently held by the government, and maybe not a full release.
To better understand what the Trump administration is planning to do with Freddie Mac and Fannie Mae—and how they're considering concerns that a release could put upward pressure on mortgage rates—we reached out to Pulte to see if he'd speak at ResiDay 2025 on Friday, November 7. He said yes.
By the time ResiDay 2025 rolls around, we may already have a much clearer picture of what the administration is planning to do—or not do—with Freddie Mac and Fannie Mae. Even then, there will be several other timely topics we'd like to ask Pulte about. That could include how they plan to implement any Freddie Mac/Fannie Mae changes; Fannie Mae and Freddie Mac accepting VantageScore 4.0 for mortgage underwriting; and his public attacks on Jerome Powell.
Here's a quick Q&A if you're looking for a refresher on Freddie Mac and Fannie Mae.
Why are Fannie Mae and Freddie Mac in conservatorship?
Fannie Mae and Freddie Mac were placed into conservatorship by the FHFA in September 2008 after suffering massive losses during the housing crash, threatening the stability of the U.S. financial system. The U.S. Treasury provided a bailout to keep them afloat, and they have remained under government control ever since—despite returning to profitability.
What do Fannie Mae and Freddie Mac do, and how do they impact the housing market?
Freddie Mac and Fannie Mae are government-backed enterprises that help keep the U.S. mortgage market running smoothly. They don't issue home loans themselves—instead, they buy mortgages from lenders, bundle them into mortgage-backed securities, guarantee those securities against default. This process creates a steady flow of capital, helping lenders offer more mortgages and keeping mortgage rates lower.
Because Freddie Mac and Fannie Mae set strict standards for the loans they buy, Freddie and Fannie shape how lenders underwrite mortgages. Their policies also influence who gets access to credit, especially first-time and lower-income buyers. During downturns, Freddie Mac and Fannie Mae, in theory, help stabilize the housing market by continuing to support lending.
While Fannie and Freddie are not officially backed by the full faith and credit of the U.S. government, they are in federal conservatorship and widely perceived as having 'implicit' government support.
What's the worst case scenario for mortgage rates if conservatorship ends without government backing?
IF Freddie Mac and Fannie Mae were fully released without an 'implicit' or 'explicit' government guarantee, Moody's chief economist Mark Zandi tells ResiClub he thinks it could push up mortgage rate by 60 bps to 90 bps. So for instance, a 60 bps increase, would push the average 30-year fixed mortgage rate today from 6.82% to 7.42%.
'Release of the GSEs as SIFIs with no government guarantee, explicit or implicit—This would add an estimated 60-90 basis points to 30-year fixed mortgage rates compared to the current status quo for the typical borrower through the business cycle. Without a government guarantee, the Federal Reserve would not be able to buy the GSEs' MBS, and there is the risk that the rating agencies would downgrade the GSEs' debt and securities. The GSEs' share of the mortgage market would significantly decline, and it would increase for private lenders and the FHA, resulting in greater taxpayer exposure, as taxpayers bear all the risk in FHA loans,' Mark Zandi told ResiClub earlier this year.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
SOUTH SAN FRANCISCO, Calif., July 15, 2025--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of Hepatology and Nutrition of the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the completed PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH). "We are pleased that the FDA has lifted the partial clinical hold on zetomipzomib in AIH after their review of our comprehensive safety assessment of the zetomipzomib program," said Chris Kirk, PhD, CEO and co-founder of Kezar. "We continue to believe that zetomipzomib has the potential to positively transform the lives of patients living with AIH. We look forward to engaging with the FDA to align on the design of the next clinical trial of zetomipzomib in AIH." Although Kezar has suspended development of zetomipzomib in lupus nephritis (LN) to focus on AIH, the company met with the Independent Data Monitoring Committee (IDMC) for the previously terminated PALIZADE clinical trial to review the safety profile of zetomipzomib. The IDMC has provided Kezar with recommendations for conducting future clinical trials in LN. Based on this feedback and internal analysis of safety data across all clinical studies involving zetomipzomib, Kezar plans to respond to the FDA Division of Rheumatology and Transplant Medicine with a request to lift the clinical hold on zetomipzomib in LN. About Zetomipzomib Zetomipzomib is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from completed clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases. About Autoimmune Hepatitis Autoimmune hepatitis (AIH) is a rare chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage, severely impacting patients' physical health and quality of life. Lifelong maintenance therapy is required to avoid relapse and burdensome adverse effects. If left untreated, AIH can lead to cirrhosis, liver failure and hepatocellular carcinoma. In the United States, AIH affects approximately 100,000 individuals, with incidence rates increasing. The cause of this condition remains unclear, with females affected four times as often as males. Currently, standard of care treatment for AIH is chronic, immunosuppressive treatment with corticosteroids that frequently cause life-altering side effects, including diabetes, osteoporotic fractures and cataracts. There is a significant need for treatment regimens that reduce or remove the need for chronic immunosuppression from use of corticosteroids. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit and follow us on LinkedIn, Facebook, Twitter and Instagram. Cautionary Note on Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "can," "should," "expect," "believe," "potential," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Kezar's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing and outcome of regulatory submissions and interactions with the FDA, EMA or any other regulatory agencies with respect to zetomipzomib or Kezar's clinical trials, the initiation of an additional clinical trial of zetomipzomib in AIH, and expectations regarding the removal of the clinical hold of zetomipzomib in LN, and the likelihood of obtaining regulatory approval of zetomipzomib. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, difficulties enrolling and conducting our clinical trials, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Kezar's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. View source version on Contacts Investor and Media Contact:Gitanjali JainSenior Vice President, Investor Relations and External AffairsKezar Life Sciences, Melden Sie sich an, um Ihr Portfolio aufzurufen.


Washington Post
24 minutes ago
- Washington Post
Google partners with Youngkin and offers AI training courses to Virginia job seekers
RESTON, Va. — Republican Gov. Glenn Youngkin announced on Tuesday that Google will partner with his administration to provide free and low-cost artificial intelligence certification courses to Virginians as part of his office's ongoing effort to connect citizens to new jobs amid changes to the state's economy. The partnership, which he has described as an AI career launchpad, will provide Google-sponsored AI training courses for up to 10,000 Virginians at any given time, officials said at Google's office in the northern part of the state.

Yahoo
25 minutes ago
- Yahoo
TribCast: Texas' redistricting gamble
Lawmakers return to Austin July 21 for a special session that will feature an extra-special, mid-decade redistricting effort. Will they get it done in 30 days? Will the new maps withstand legal scrutiny? Will this threaten congressional Republicans' seats long-term? Will it appease President Donald Trump, who says he wants five new seats for the GOP in Texas? Matthew and Eleanor dig into all this and more with Kareem Crayton, with the Brennan Center for Justice. Watch the video above, or subscribe to the TribCast on iTunes, Spotify, or RSS. New episodes every Tuesday. Shape the future of Texas at the 15th annual , happening Nov. 13–15 in downtown Austin! We bring together Texas' most inspiring thinkers, leaders and innovators to discuss the issues that matter to you. Get tickets now and join us this November. TribFest 2025 is presented by JPMorganChase.